The Full Court has overturned a finding that singer Katy Perry infringed an Australian fashion designer’s ‘Katie Perry’ mark, finding the designer knew of the pop star when she registered the mark.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
AI tech company Paige can’t patent a tool to provide quality control for analysis of pathology images, with IP Australia finding the invention is merely an “administrative scheme” to automate the role of human pathologists.
US animal drug manufacturer Zoetis has lost its challenge a ruling that chucked out three of its patents for a single-dose vaccine to protect pigs from enzootic pneumonia.
US men’s magazine Maxim is seeking an injunction against its “out of control” Australian licensee, which it accuses of running modelling tours for an offshoot brand that are below its standards.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.
The ATO has won the nod from the High Court to appeal a finding that a royalty withholding tax did not apply to payments from Schweppes to PepsiCo under agreements to sell brands like Pepsi and Gatorade in Australia.
Vittoria has defeated claims in an intellectual property battle that it infringed on rival Koninklijke Douwe Egbert’s trade mark for the design of its Moccona instant coffee jar.
NAB has successfully opposed a US company’s bid to register a trade mark for ‘UWallet’, with IP Australia rejecting claims the bank was trying to establish a “de facto monopoly”.
The Commonwealth has lost its bid to pause a long-running dispute over a generic form of brand drug Abilify while the High Court hears a different generic drug battle.